Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography or PET-computed tomography in cervical cancer : A meta-analysis

International Journal of Gynecological Cancer

Volumn 23, Issue 7, 2013, Pages 1184-1190

  Zhao, Qianying ^a   Feng, Yi ^a   Mao, Xuanyue ^b   Qie, Mingrong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cervical cancer; Fluorine 18 fluorodeoxyglucose (18F FDG); PET CT; Positron emission tomography (PET); Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; EMBASE; EVENT FREE SURVIVAL; HUMAN; MEDLINE; METABOLISM; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS;

EID: 84884520610     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31829ee012     Document Type: Review

References (30)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
2. Siva S, Herschtal A, Thomas JM, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer. 2011;117:3981-3988.
3. Benedet JL, Odicino F, Maisonneuve P. Carcinoma of the cervix uteri. J Epidemiol Biostat. 2001;6:7-43.
4. Belhocine TZ. 18F-FDG PET imaging in posttherapy monitoring of cervical cancers: from diagnosis to prognosis. J Nucl Med. 2004;45:1602-1604.
5. Kumar R, Dadparvar S. 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (PET)/PET-computed tomography in carcinoma of the cervix. Cancer. 2007;110:1650-1653.
6. Kidd EA, Siegel BA, Dehdashti F, et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738-1744.
7. Bjurberg M, Kjellén E, Ohlsson T, et al. Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer. Int J Gynecol Cancer. 2009;19: 1600-1605.
8. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
9. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
10. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19:3745-3749.
11. Nakamoto Y, Eisbruch A, Achtyes ED, et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol. 2002;84:289-295.
12. Unger JB, Lilien DL, Caldito G, et al. The prognostic value of pretreatment 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography scan in women with cervical cancer. Int J Gynecol Cancer. 2007;17:1062-1067.
13. Dolezelova H, Slampa P, Ondrova B, et al. The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma: results of pilot study. Neoplasma. 2008;55:437-441.
14. Lee YY, Choi CH, Kim CJ, et al. The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol Oncol. 2009;115:65-68.
15. Narayan K, Fisher RJ, Bernshaw D, et al. Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent. Int J Gynecol Cancer. 2009;19:912-918.
16. Chou HH, Chang HP, Lai CH, et al. (18)F-FDG PET in stage IB/IIB cervical adenocarcinoma/adenosquamous carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:728-735.
17. Kidd EA, Siegel BA, Dehdashti F, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol. 2010;28:2108-2113.
18. Small W Jr, Vern TZ, Rademaker A, et al. A prospective trial comparing lymphangiogram, cross-sectional imaging, and positron emission tomography scan in the detection of lymph node metastasis in locally advanced cervical cancer. Am J Clin Oncol. 2010;33:89-93.
19. Kang S, Park JY, Lim MC, et al. Pelvic lymph node status assessed by 18F-fluorodeoxyglucose positron emission tomography predicts low-risk group for distant recurrence in locally advanced cervical cancer: A prospective study. Int J Radiat Oncol Biol Phys. 2011;79:788-793.
20. Nakamura K, Joja I, Kodama J, et al. Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer. Eur J Nucl Med Mol Imaging. 2012;39:283-290.
21. Pan L, Cheng J, Zhou M, et al. The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol. 2012;138:239-246.
22. Yoo J, Choi JY, Moon SH, et al. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer. 2012;22:1226-1233.
23. Schwarz JK, Siegel BA, Dehdashti F, et al. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2012;83:185-190.
24. Stehman FB, Bundy BN, DiSaia PJ, et al. Carcinoma of the cervix treated with irradiation therapy: I. A multivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991;67:2776-2785.
25. Amit A, Schink J, Reiss A, et al. PET/CT in gynecologic cancer: present applications and future prospectsYa clinician's perspective. Obstet Gynecol Clin North Am. 2011;38:1-21.
26. Scheidler J, Hricak H, Yu KK, et al. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA. 1997;278:1096-1101.
27. Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET. Cancer Imaging. 2008;8:70-80.
28. Sironi S, Buda A, Picchio M, et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology. 2006;238:272-279.
29. Shield PW, Daunter B, Wright RG. Post-irradiation cytology of cervical cancer patients. Cytopathology. 1992;3:167-182.
30. Xie P, Li M, Zhao H, et al. 18F-FDG PETor PET-CT to evaluate prognosis for head and neck cancer: A meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085-1093.